Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Working Capital Changes (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Other Working Capital Changes data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Other Working Capital Changes rose 1391.13% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $8.9 million, up 252.45%, while the annual FY2024 figure was $7.7 million, 1178.57% up from the prior year.
  • Other Working Capital Changes reached $1.6 million in Q3 2025 per ZBIO's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.1 million in Q4 2024 and bottomed at -$5.4 million in Q4 2023.
  • Average Other Working Capital Changes over 3 years is $384000.0, with a median of $114500.0 recorded in 2024.
  • The widest YoY moves for Other Working Capital Changes: up 1391.13% in 2025, down 177.94% in 2025.
  • A 3-year view of Other Working Capital Changes shows it stood at -$5.4 million in 2023, then surged by 249.78% to $8.1 million in 2024, then crashed by 80.31% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $1.6 million in Q3 2025, -$1.2 million in Q2 2025, and $353000.0 in Q1 2025.